OncoVista Innovative Therapies, Inc. Retains Great Plains Capital As A Financial Advisor

SAN ANTONIO--(BUSINESS WIRE)--Oncovista Innovative Therapies, Inc. (OTCBB: OVIT) (“Oncovista” or the “Company”) is pleased to announce it has retained Great Plains Capital Partners, LLC (“GPCP” or “advisor”) as a financial advisor. GPCP, in a consultant capacity, will focus on strategic and corporate planning including assistance with mergers & acquisitions, and other strategic initiatives to ultimately help drive shareholder value for the investors of Oncovista. The Company recently settled a long-term litigation case that worked out to be very favorable, and plans to continue to advance and grow its pipeline.

“We are delighted to partner with Oncovista in the value creation components of its corporate strategy.”

Rex Wiggins, Managing Director of GPCP, commented, “We are delighted to partner with Oncovista in the value creation components of its corporate strategy.” Mr. Wiggins has extensive bio-technology experience including a recent 5 year stint as COO at a Midwestern clinical stage Cancer Immunotherapy company.

Alexander L. Weis, CEO of Oncovista, commented: “We are pleased to work with Great Plains Capital Partners. The Company has a great opportunity to advance the most efficient anticancer drugs, help cancer patients and create huge returns to investors.”

About Oncovista

Oncovista Innovative Therapies, Inc., a biopharmaceutical company that develops targeted anticancer therapies by utilizing tumor-associated biomarkers. Its drug candidate pipeline includes Cordycepin (OVI-123), which is in Phase I/II clinical trials for the treatment of Refractory TdT Positive Leukemias; and L-Nucleoside Conjugates (OVI-117) that is in Phase I clinical development for the treatment of Colon Cancer. The company was founded in 2004 and is based in San Antonio, Texas.